• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Children conceived after fertility treatments are at increased risk for pediatric cancers

Bioengineer by Bioengineer
April 25, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

BEER-SHEVA, Israel…April 25, 2017 – Ben-Gurion University of the Negev (BGU) researchers have found that babies born from mothers who underwent fertility treatments are at increased risk of developing many types of pediatric cancers and tumors (neoplasms).

According to the American Cancer Society, the most common pediatric neoplasms are leukemia, brain and spinal cord tumors, neuroblastomas, Wilms tumors, and lymphoma, including both Hodgkin and non-Hodgkin.

The study, published in the March issue of the American Journal of Obstetrics & Gynecology, was a population-based cohort analysis of babies born between 1991 and 2013 at Soroka University Medical Center in Beer-Sheva, Israel, with follow-up to age 18.

"In Israel, all fertility interventions, which include in vitro fertilization (IVF) and ovulation induction (OI), are fully covered by insurance, enabling citizens of all backgrounds access to these treatments," says Prof. Eyal Sheiner, M.D., Ph.D., vice dean of the BGU Faculty of Health Sciences (FOHS), member of its Department of Obstetrics and Gynecology, and a physician at Soroka.

Of the 242,187 newborn infants in the study, 237,863 (98.3 percent) were conceived spontaneously; 2,603 (1.1 percent) were conceived after in vitro fertilization, and 1,721 (0.7 percent) were conceived after ovulation induction treatments.

During the follow-up period of approximately 10.6 years, 1,498 neoplasms (0.6 percent) were diagnosed. The incidence rate for neoplasms was highest among children either after IVF (1.5/1000) and somewhat lower for OI births (1.0/1000) as compared to that of naturally conceived children (.59/1000).

"The research concludes that the association between IVF and total pediatric neoplasms and malignancies is significant," Prof. Sheiner says. "With increasing numbers of offspring conceived after fertility treatments, it is important to follow up on their health."

###

Other researchers who participated in the study include Prof. Tamar Weinstock, Prof. Ilana Shoham-Vardi and Ruslan Sergienko, BGU Department of Public Health; Dr. Daniella Landau, BGU Department of Pediatrics; Drs. Ari Harlev and Asnat Walfisch, BGU Department of Obstetrics and Gynecology; and Dr. Idit Segal, Israel Ministry of Health.

About American Associates, Ben-Gurion University of the Negev

American Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe. As Ben-Gurion University of the Negev (BGU) looks ahead to turning 50 in 2020, AABGU imagines a future that goes beyond the walls of academia. It is a future where BGU invents a new world and inspires a vision for a stronger Israel and its next generation of leaders. Together with supporters, AABGU will help the University foster excellence in teaching, research and outreach to the communities of the Negev for the next 50 years and beyond. Visit vision.aabgu.org to learn more.

AABGU, which is headquartered in Manhattan, has nine regional offices throughout the United States. For more information, visit http://www.aabgu.org.

Media Contact

Andrew Lavin
[email protected]
516-944-4486

http://www.aabgu.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Circ_0000847 Drives Colorectal Cancer via IGF2BP2 Binding

August 22, 2025
Sensitive Surfaces and Keen Senses: Innovative Robotics Detect Threats Before Impact

Sensitive Surfaces and Keen Senses: Innovative Robotics Detect Threats Before Impact

August 22, 2025

ATOX1 Drives Hepatocellular Carcinoma Progression by Activating the c-Myb/PI3K/AKT Signaling Pathway

August 22, 2025

Unraveling Fat Maps: Microfluidics and Mass Spectrometry Illuminate Lipid Landscapes in Tiny Worms

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Circ_0000847 Drives Colorectal Cancer via IGF2BP2 Binding

Sensitive Surfaces and Keen Senses: Innovative Robotics Detect Threats Before Impact

ATOX1 Drives Hepatocellular Carcinoma Progression by Activating the c-Myb/PI3K/AKT Signaling Pathway

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.